- Juva Life (JUVA) has announced the successful scale-up of the promising proprietary molecule, JUVA-041, from a microgram quantity to a 5-gram quantity
- The company notes that its approach through its proprietary platform is proving to be successful, showcasing superior medicinal chemistry, and a large commercial advantage
- This strategy will not only allow for the identification of new compositions of matter but ones that are scalable and affordable
- The company describes JUVA-041 as a small molecule isolated from cannabis uniquely identified by Juva Life’s research team
- Juva Life is a company in the cannabis market
- Juva Life Inc. opened trading at $0.145 per share
Juva Life (JUVA) has announced the successful scale-up of the promising proprietary molecule, JUVA-041, from a microgram quantity to a 5-gram quantity.
The company noted that its approach through its proprietary platform is proving to be successful, showcasing superior medicinal chemistry and a large commercial advantage.
This strategy will not only allow for the identification of new compositions of matter but ones that are scalable and affordable.
“Novel compound Juva-041 has demonstrated potent anti-inflammatory properties in phenotypic assays of inflammation and is now being scaled up to support pre-clinical studies,” noted Doug Chloupek, CEO and Founder of Juva.
“Through Juva’s proprietary platform, we have made significant developments identifying the method and mode of action behind cannabis’ anecdotal therapeutic potential. This scale-up hurdle we have crossed allows us a straight shot for commercial development devoid of manufacturing obstacles,” he added.
According to Juva, one of the most significant challenges companies face is the scale-up of starting material and the creation of finished drug products to support the FDA-required non-clinical studies.
This has significantly hampered existing pharmaceutical and consumer approaches. Juva has discovered novel compounds JUVA-019 and JUVA-041 that have shown superior anti-inflammatory drug properties compared to many commercially available products.
This provides Juva with a significant development, and commercial advantage as the speed of learning and cost of development is significantly less than established pharmaceutical approaches.
The company describes JUVA-041 as a small molecule isolated from cannabis uniquely identified by Juva Life’s research team.
Juva Life is a company in the cannabis market.
Juva Life Inc. opened trading at $0.145 per share.
